Normalization by Ligation™ library preparation
technology processes thousands of samples at low cost with enhanced
multiplexing and novel streamlined workflow
Designed with a Twist-developed enzyme
specifically to increase adoption of NGS workflows in high
throughput applications
Collaboration with Gencove to offer access to
software to perform genomic analysis, enabling an end-to-end sample
to variant call workflow
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the launch of the
FlexPrep™ Ultra-High Throughput Library Preparation
Kit, designed with a proprietary Twist-developed enzyme to enable
throughput at a low cost, and accelerate the adoption of NGS by
microarray users in population and agricultural genomics
(agrigenomics).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20241030111770/en/
Advanced sequencing technologies continue to drive increased
sample volumes across multiple applications. The desire to profile
tens of thousands to millions of samples in parallel, beyond just
single nucleotide polymorphisms (SNPs), requires a next-generation
sequencing (NGS) solution that enables high throughput applications
at a reasonable cost. The Twist FlexPrep UHT Library Prep kit
improves upon standard enzymatic fragmentation library preparation
methods with the introduction of a novel Normalization by
Ligation™ (NBL) technology, which eliminates the need
for time-consuming upfront sample quantitation, and enables sample
pooling and multiplexing early in the workflow. This built-in
normalization and multiplexing capability simplifies how
researchers prepare samples with variable mass at scale, where
efficiency in workflow and per-sample cost is critical for NGS
implementation1.
“At Twist, we continue to push the boundaries of what
applications can be made possible with synthetic DNA and to develop
products that open up new markets. Legacy methods of profiling very
large numbers of samples for agrigenomics to genotype cows, pigs
and other animals as well as for population genomics studies, have
not kept pace with evolving NGS methods and are tied to a fixed set
of markers. Innovative next-generation sequencing methods provide
far superior data to microarray technology, with the Twist FlexPrep
UHT Kit surpassing even the most advanced NGS methods to maximize
throughput and minimize cost,” said Emily M. Leproust, Ph.D., CEO
and co-founder of Twist Bioscience. “When conducting large scale
experiments and running multiple samples in parallel, researchers
must ensure that there is equivalent mass of each sample included,
and this ‘normalization’ process takes time, energy and effort.
Using a novel technology, the FlexPrep UHT Kit self-normalizes,
eliminating a critical time-consuming step while at the same time
enabling high throughput, streamlining workflows and enabling
scalability and customization. In addition to the differentiating
capabilities of the kit, we’re collaborating with Gencove to offer
a complementary genomic analysis solution to our customers.”
With the Twist FlexPrep UHT kit, researchers can run up to 1,152
samples in a single 96-well plate sequencing run, which can save
researchers time and costs. And compared to processing samples
individually, FlexPrep reduces consumables used by a factor of 12
as well as reduces the number of pipette tips from over 17,000 used
in a standard kit to under 4,000 with the FlexPrep UHT kit.
Designed for automation and to enable scientists to confidently
multiplex, the NBL technology simultaneously tags samples with a
unique barcode to enable early pooling of up to 12 separate samples
in one reaction, delivering 12x improvement on consumables and
reagent efficiency1. Utilizing this tagging method together with
Twist’s 3,000 unique dual indexes (UDIs) in the FlexPrep workflow,
research sample sizes are not constrained by multiplexing capacity
or throughput. The FlexPrep UHT kit can also be paired with Twist’s
custom target enrichment panels for tunable and uniform coverage of
genomic regions of interest.
“The normalization adapters enable us to skip costly
quantification steps, and the sample barcodes reduce the number of
PCR reactions, cleanups, and use of tips by 12-fold. Not only does
FlexPrep increase our throughput, it saves us time and money,”
commented Angela Jones, NGS operations manager at Vanderbilt
University Medical Center.
Twist is also collaborating with Gencove, a leader in low-pass
genome sequencing methods and analysis software, to offer analysis
solutions to customers using FlexPrep UHT to understand their data
and deliver fast, cost-effective and accurate genotyping results.
Gencove works in a partnership model to design custom assays,
optimize sequencing solutions, and build analysis pipelines to
effectively bridge the gap from samples to solutions in the fields
of agriculture and human health.
“Low-pass sequencing and imputation, or enhanced whole genome
sequencing with target enrichment to dive deeper into regions of
interest, are ideal workflows for anyone initiating a genotyping
program for the first time or looking to replace outdated arrays
with a cost-effective, flexible and information rich solution,”
said Joe Pickrell, Co-founder and CEO, Gencove. “To meet the
growing demand for large-scale genomic information, we’ve developed
an end-to-end software solution that we’re pleased to offer as an
additional tool for Twist’s customers using FlexPrep UHT and
embracing NGS technology to expand their high throughput and
genomic analysis capabilities beyond what is offered by
microarrays.”
Twist FlexPrep™ Ultra-High Throughput
(UHT) Library Preparation Kit
The Twist Flex Prep™ UHT Kit workflow is
purpose-built to streamline and massively scale up Twist’s
established enzymatic fragmentation methods. The Normalization by
Ligation™ (NBL) technology eliminates the need to
measure the mass of each DNA sample and to perform labor-intensive
concentration adjustment prior to library preparation, saving
significant cost per sample. Following fragmentation and adapter
ligation of each sample in a plate, up to 12 samples are pooled
together in a single tube. This pooling strategy results in a
meaningful reduction in both volumes and costs of reagents required
for subsequent bead purification and amplification steps1.
Libraries prepared from this kit can be leveraged to perform whole
genome or targeted sequencing with the use of target enrichment
panels. All plate and tube formats are optimized to ensure
compatibility with key automation systems, a critical consideration
for labs looking to streamline workflows and reduce hands-on
time.
1As compared to Twist Library Preparation EF Kit 2.0.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on LinkedIn | X | YouTube | Instagram
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements with respect to the potential savings
resulting from integrating Twist products into a workflow, the
success of our collaboration with Gencove and ability of the
complementary genomic analysis solution to meet our customers’
needs. Forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
ability to achieve the expected benefits of Twist Bioscience’s
restructuring activities and reduced investments in DNA data
storage; the ability to attract new customers and retain and grow
sales from existing customers; the ability of Twist Bioscience to
achieve sufficient revenue to achieve or maintain positive cash
flow from operations or profitability, which will depend heavily on
the success of its existing products and the development and
commercialization of additional products in the synthetic biology,
biologic drug and data storage industries; risks and uncertainties
of rapidly changing technologies and extensive competition in
synthetic biology that could make the products Twist Bioscience is
developing obsolete or non-competitive; uncertainties about the
retention of significant customers; the ability of Twist Bioscience
to successfully integrate acquired companies and to achieve
expected benefits from acquisitions; supply chain and other
disruptions; risks of third party claims alleging infringement of
patents and proprietary rights or seeking to invalidate Twist
Bioscience’s patents or proprietary rights; and the risk that Twist
Bioscience’s proprietary rights may be insufficient to protect its
technologies. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Annual Report on Form 10-K
filed with the SEC on November 21, 2023 and subsequent filings with
the SEC. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Twist Bioscience
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241030111770/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Manager
774-265-5334 ahoulihan@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
